Candel Therapeutics, Inc. (CADL) vs Rigel Pharmaceuticals, Inc. (RIGL)

Candel Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Candel Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($894.6M and $883.8M). Candel Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.7×. Rigel Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 3.31% against 0.00%. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs 0.00%) and the higher return on invested capital (16.5% vs 0.00%). Across the 17 metrics below, Rigel Pharmaceuticals, Inc. leads on 16 and Candel Therapeutics, Inc. on 1.

Valuation

Metric CADL RIGL Biotechnology median
P/E n/m 2.73 7.88
P/S 6,535.41 3.23 11.47
P/B 6.48 2.10 2.52
Price to free cash flow n/m 99.48 21.16
EV/EBITDA n/m 9.16 0.74
EV/Sales 5,339.33 2.94 10.73
Earnings yield (12.79%) 36.67% (28.84%)
Free cash flow yield (7.01%) 1.01% (23.03%)

Profitability

Metric CADL RIGL Biotechnology median
Gross margin 0.00% 91.39% 65.16%
Operating margin 0.00% 31.45% 0.00%
Net margin 0.00% 116.30% 0.00%
Free cash flow margin 0.00% 3.19% 0.00%
Return on equity (81.84%) 126.90% (57.72%)
Return on assets (56.37%) 88.46% (49.22%)
Return on invested capital 0.00% 16.48% 0.00%

Growth

Metric CADL RIGL Biotechnology median
Revenue growth (TTM) 0.00% 3.31% 5.64%
EPS growth (last fiscal year) 58.62% 1,867.68% —
Revenue growth, 5-year CAGR — 22.06% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CADL RIGL Biotechnology median
Debt to equity 0.38 0.00 0.00
Current ratio 16.09 1.94 4.73
Net debt to EBITDA 1.53 (1.05) 0.96

Dividend

Metric CADL RIGL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CADL RIGL Biotechnology median
Market cap 883.79m 894.58m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack